Quantum redactiones paginae "Opicaponum" differant
Content deleted Content added
m ad usum |
|||
Linea 34:
|}
'''Opicaponum''' (abbreviatura: '''OPC''') est [[medicamentum pharmaceuticum]] imprimis [[neurologia]]e in [[morbus Parkinson|morbo Parkinson]] tractando. Substantia gregi [[inhibitor catechol-O-methyltransferasis|inhibitorum COMT]] attribuitur, quod est, ut enzymum COMT ([[catechol-O-methyltransferasis]]) inhibitur. Prae aliis gregum horum effectus Opicaponi longius sunt.
Adhuc hepatotoxici effectus [[Tolcaponum|Tolcaponi]] incogniti sunt<ref name="SCOTT16">{{cite journal |authors=Scott L. J. |title=Opicapone: A Review in Parkinson's Disease |journal=Drugs |year=2016 |month=Sep |volume=76 |issue=13 |pages=1293-1300 |url=https://www.ncbi.nlm.nih.gov/pubmed/27498199/}}</ref>.
== Natura Opicaponi ==
Line 57 ⟶ 59:
== Usus medicus ==
Quamquam [[tempus semivitae biologicum]] eius valde breve est, prae aliis inhibtoribus COMT ut [[Entacaponum|Entacapono]] vel [[Tolcaponum|Tolcapono]] spatium effectuum longius sustinetur, paene viginti quattuor horae<ref>{{cite journal |authors=Rocha J. F., Almeida L., Falcão A., Palma P. N., Loureiro A. I., Pinto R., Bonifácio M. J., Wright L. C., Nunes T., Soares-da-Silva P. |title=Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects |journal=British journal of clinical pharmacology |year=2013 |month=Nov |volume=76 |issue=5 |pages=763-75 |url=https://www.ncbi.nlm.nih.gov/pubmed/23336248}}</ref>.
Dosis 50 mg Opicaponi vesperi<ref name="SCOTT16" /> cum intervallo unae horae L-DOPA commendata est.
== Notae ==
| |||